#United States #Robbins Geller #San Diego #Securities Class Action #Ultragenyx

Ultragenyx Pharmaceutical Inc. Investors: Class Action Lawsuit Opportunity

In a significant development for investors, Robbins Geller Rudman & Dowd LLP has announced a deadline for shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) who experienced substantial losses to step forward and potentially lead a class action lawsuit. This opportunity arises for those who purchased the company’s common stock during the class period from August 3, 2023, to December 26, 2025.

The Case Background

The lawsuit, titled Bailey v. Ultragenyx Pharmaceutical Inc. (No. 26-cv-01097), accuses multiple defendants, including top executives at Ultragenyx, of violating the Securities Exchange Act of 1934. The claims suggest that during the specified period, misleading statements regarding the company's clinical trials and product safety were made, creating a false sense of security among investors.

Ultragenyx is primarily a biopharmaceutical firm focused on developing treatments for rare genetic disorders. The allegations state that the defendants misrepresented the viability of setrusumab, a drug aimed at treating Osteogenesis Imperfecta (OI). Specifically, it is contended that they downplayed the risks involved in the Phase III Orbit study, which ultimately failed to provide statistically significant results.

Key Allegations

The crux of the lawsuit highlights two major concerns: 1) Ultragenyx allegedly misled investors about the efficacy of setrusumab based on non-comparable Phase II trial results lacking a placebo control group, and 2) they failed to adequately inform shareholders of the risks associated with these studies, leading to inflated stock prices.

The stakes became painfully clear for investors when, on July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study had not achieved the anticipated statistical significance. Consequently, the company's stock plummeted more than 25% in value. A subsequent announcement on December 29, 2025, revealed that not only had the Orbit study failed, but so had related studies, causing a staggering 42% drop in stock price.

Investor Participation

Under the Private Securities Litigation Reform Act of 1995, investors suffering losses from purchasing Ultragenyx stock during the class period can apply to serve as lead plaintiffs in this lawsuit. The lead plaintiff typically holds the greatest financial interest in the outcome of the case and represents all affected shareholders.

This process provides a platform for the lead plaintiff to select legal representation of their choice for litigation proceedings. Importantly, potential claims to recover losses do not hinge on whether an individual serves as the lead plaintiff, encouraging wider participation in the action.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as one of the premier firms specializing in complex class actions, particularly in the realm of securities fraud. With a proven track record, the firm recovered over $916 million for investors in 2025 alone, further asserting their expertise in this field. Their reputation is bolstered by a history of achieving some of the largest recoveries in U.S. securities class action litigation, preparing them to competently represent affected Ultragenyx investors.

Conclusion

Current and former investors of Ultragenyx Pharmaceutical Inc. are encouraged to assess their involvement from August 2023 to December 2025 closely. Those who wish to explore their options regarding participating in the class action lawsuit should reach out to Robbins Geller Rudman & Dowd LLP by April 6, 2026, to ensure they do not miss the opportunity to advocate for their rights and potential financial recovery. For more information, interested investors can visit Robbins Geller or contact attorney J.C. Sanchez directly.

Investors should act swiftly, as these legal opportunities often come with tight timelines, especially when significant financial interests are at stake.